Developer docs
API playgroundTry for free, no card

Search company profiles

CILcare

Full company profile

uuid000255n

Namestring
CILcare
Legal namestring
CILcare S.A.S
Websiteurl
cilcare.com
Company typeenum
Private
Founded yearint
2014
Short descriptiontext

CILcare is a Montpellier-based biotech providing specialized auditory R&D services to pharma, biotech, medtech, and academic clients globally, while developing its own lead drug candidate CIL001 for cochlear synaptopathy and tinnitus.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMontpellier, France
HQ citystring
Montpellier
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
auditory drug development, hearing loss therapeutics, preclinical CRO services, ototoxicity testing, tinnitus treatment
Industry4 codes
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Other Scientific and Technical Consulting Services54169
  • Custom Computer Programming Services541511
SIC code3 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Prepackaged Software7372
Product category
Hearing Therapeutics R&D Services
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services (CRO)
TypeProfessional Services
Description

Cilcare provides its smart R&D platform as research-for-hire to pharmaceutical companies, biotechs, medtech firms, and academic institutions in Europe, US, and Asia. Services include preclinical studies, PK/PD studies, ototoxicity testing, and regulatory support for hearing drug development.

cilcare.com
2Proprietary Drug Development
TypeLicensing Royalties
Description

Cilcare develops its own portfolio of drug candidates targeting cochlear synaptopathy and other auditory disorders. Lead candidate CIL001 is advancing through Phase 2a clinical trials for tinnitus and other indications.

cilcare.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1CILcare Auditory Analytics
Description

AI-driven hearing analysis platform positioning hearing as a key asset of preventive medicine and global healthcare monitoring, utilizing auditory measurements to define digital auditory signatures.

cilcare.com
+2 more records
Core offering1 text field

CILcare is a French biotechnology company that provides contract research services (CRO) and develops proprietary drug candidates targeting hearing and ear disorders. Through its External Innovation division, it offers a comprehensive auditory R&D platform spanning in vitro, ex vivo, and in vivo pharmacological models, GLP-compliant ototoxicity studies, electrophysiology, behavioral assessments, histopathology, and surgical capabilities for pharmaceutical, biotech, medtech, and academic clients in Europe, the US, and Asia. Through its Therapeutics division, it advances its own drug pipeline, notably CIL001 for cochlear synaptopathy/tinnitus, and through its Auditory Analytics division, it operates an AI-driven platform that derives digital auditory signatures from patient measurements and biomarkers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 26% of cognitively preserved diabetic patients presented clinical signs of hidden hearing loss in DIAMANT study
+2 more records
Product overview1 text field

CILcare is a biotech company organized into three interconnected divisions: (1) External Innovation – a comprehensive R&D platform offering pharmacological models, GLP toxicology, electrophysiology, and surgical services to support partners in developing drugs, gene/cell therapies, and medical devices for hearing disorders; (2) Therapeutics – advancing proprietary drug candidates including CIL001 (lead compound for cochlear synaptopathy/tinnitus in Phase 2a) and CIL003, leveraging AI and real-world data; and (3) Auditory Analytics – an AI-driven platform developing digital auditory signatures from auditory measurements and biomarkers for early detection of hearing impairment and associated diseases. The company conducts observational clinical studies (DIAMANT, SAPHIR) to characterize auditory profiles in specific patient populations and refine clinical trial protocols.

Product and service3 records
1CILcare External Innovation (R&D Platform)
CategoryContract Research Services (CRO) for Auditory Drug Development
Description

Comprehensive contract research (CRO) R&D platform offering pharmacological models, GLP toxicology, electrophysiology (ABR, DPOAE, Wave I-V), behavioral assessments (GPIAS, PPI, tinnitus detection), histopathology, inner ear surgery, drug delivery (transtympanic, intracochlear, systemic), and biomarker studies. Used by pharmaceutical, biotech, medtech, and academic clients to evaluate drug candidates, gene therapies, cell therapies, and medical devices for hearing disorders.

2CIL001
CategoryProprietary Drug Candidate (Pipeline)
Description

Proprietary lead drug candidate targeting cochlear synaptopathy, the mechanism underlying difficulty understanding speech in noisy environments, tinnitus, and hyperacusis. Advancing through Phase 2a clinical evaluation for tinnitus and other indications, with clinical trials at Massachusetts General Hospital (US) and other sites.

3CILcare Auditory Analytics
CategoryAI-Driven Auditory Analytics Platform
Description

AI-driven analytics platform utilizing patient auditory measurements (ABR, DPOAE, speech-in-noise testing) combined with biomarkers and proprietary algorithms/deep learning to define digital auditory signatures for characterizing hearing impairments and supporting early detection of neurocognitive and inflammatory diseases. Used to inform clinical trial patient stratification and preventive medicine positioning.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-06-23
Description

Updated license deal with Sanofi who becomes an equity holder, demonstrating deepened commitment to hearing loss therapies. Sanofi has been a long-term licensing partner for hearing-related programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Nine-year collaboration since 2017 with CBSET, a leading preclinical biomedical research organization in Massachusetts. CBSET is tripling its laboratory capacity, enabling Cilcare to significantly scale up hearing research operations in the US. Together they offer a turnkey model for international companies seeking US market entry.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Clinical trial of CIL001 in tinnitus being conducted at MGH in Boston in partnership with Professor Stéphane Maison, an internationally recognized leader in auditory neuroscience. This marks the first evaluation of CIL001 in patients with chronic tinnitus on US soil.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-10
Description

Strategic agreement with CTIBIOTECH and SATT AxLR to develop 3D bioprinted inner ear organoids from human induced pluripotent stem cells for pharmacological screening in hearing disorders. The OrgaEar project aims to enable mass production and reduce animal testing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-10
Description

Technology transfer office supporting the OrgaEar project for 3D bioprinted inner ear organoid development in collaboration with CTIBIOTECH and Cilcare.

6University Hospital Gui de Chauliac (Montpellier)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner in the SAPHIR observational clinical study investigating hearing impairments in patients with mild cognitive impairment and Parkinson's disease.

cilcare.com
7University Hospital Carémeau (Nîmes)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner in the SAPHIR study alongside Gui de Chauliac for multicenter, prospective clinical research on hearing and neurodegenerative diseases.

cilcare.com
8Hospices Civils de Lyon
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner in the SAPHIR study for investigating hearing profiles in early-stage neurodegenerative diseases across three patient groups.

cilcare.com
9IDNC (Institute of Diabetology and Nutrition of Centre)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Primary site for the DIAMANT observational clinical study, conducted in association with LNA Health research center, investigating hearing profiles in type 2 diabetes patients.

cilcare.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Preclinical CRO with research models and toxicology services including hearing-related endpoints; comparable as a scaled preclinical services competitor to CILcare's CRO division.

TypeDirect peer
Description

Preclinical CRO partner in Massachusetts offering translational research services; directly comparable as a specialty preclinical CRO with cardiovascular/otology capabilities.

TypeDirect peer
Description

Gene-therapy biotech for inner-ear disorders; comparable specialty therapeutic focus on auditory drug development including modalities CILcare supports as a CRO.

TypeBroad incumbent
Description

Largest preclinical CRO offering broad safety assessment and research models including ototoxicology services; comparable as a potential large-scale competitor in auditory preclinical work.

TypeBroad incumbent
Description

Global CRO with extensive central laboratory, bioanalytical, and early development services; comparable end-to-end clinical research services that overlap with CILcare's External Innovation offering.

TypeEmerging player
Description

Emerging biotech pursuing regenerative approaches to sensorineural hearing loss; partial overlap in therapeutic area with CILcare's lead indication.

7Otonomy
TypeDirect peer
Description

Clinical-stage biopharma developing drugs for ear disorders including tinnitus and hearing loss; directly comparable to CILcare's Therapeutics division and lead indication space.

TypeDirect peer
Description

French clinical-stage biotech focused on hearing loss therapies including tinnitus and cochlear indications; highly comparable specialty therapeutic-area positioning to CILcare.

TypeDirect peer
Description

Clinical-stage biotech developing regenerative therapies for hearing loss; comparable therapeutic-area focus and clinical-stage profile to CILcare's CIL001 program.

TypeDirect peer
Description

Gene-therapy biotech for hearing (acquired by Eli Lilly); directly comparable therapeutic-area focus on cochlear synaptopathy and hearing regeneration pathways.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CILcare

Hearing Therapeutics R&D Servicescilcare.com

CILcare is a Montpellier-based biotech providing specialized auditory R&D services to pharma, biotech, medtech, and academic clients globally, while developing its own lead drug candidate CIL001 for cochlear synaptopathy and tinnitus.

CILcare firmographics

Firmographics
Name
CILcare
Legal name
CILcare S.A.S
Website
https://cilcare.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
CILcare is a Montpellier-based biotech providing specialized auditory R&D services to pharma, biotech, medtech, and academic clients globally, while developing its own lead drug candidate CIL001 for cochlear synaptopathy and tinnitus.
Ownership category
akta.pro rank

CILcare industry classification

Industry
Product category
Hearing Therapeutics R&D Services
NAICS
Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169), Custom Computer Programming Services (541511)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs

Keywords

  • Auditory drug development
  • Hearing loss therapeutics
  • Preclinical CRO services
  • Ototoxicity testing
  • Tinnitus treatment

Where CILcare is headquartered

Location

Headquarters

HQ city
Montpellier
HQ country
France
HQ region
Europe

Offices3 records

Markets served

CILcare business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Services (CRO): Cilcare provides its smart R&D platform as research-for-hire to pharmaceutical companies, biotechs, medtech firms, and academic institutions in Europe, US, and Asia. Services include preclinical studies, PK/PD studies, ototoxicity testing, and regulatory support for hearing drug development.
  2. Proprietary Drug Development: Cilcare develops its own portfolio of drug candidates targeting cochlear synaptopathy and other auditory disorders. Lead candidate CIL001 is advancing through Phase 2a clinical trials for tinnitus and other indications.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

CILcare product offering

Product offering

Core offering

CILcare is a French biotechnology company that provides contract research services (CRO) and develops proprietary drug candidates targeting hearing and ear disorders. Through its External Innovation division, it offers a comprehensive auditory R&D platform spanning in vitro, ex vivo, and in vivo pharmacological models, GLP-compliant ototoxicity studies, electrophysiology, behavioral assessments, histopathology, and surgical capabilities for pharmaceutical, biotech, medtech, and academic clients in Europe, the US, and Asia. Through its Therapeutics division, it advances its own drug pipeline, notably CIL001 for cochlear synaptopathy/tinnitus, and through its Auditory Analytics division, it operates an AI-driven platform that derives digital auditory signatures from patient measurements and biomarkers.

Product overview

CILcare is a biotech company organized into three interconnected divisions: (1) External Innovation – a comprehensive R&D platform offering pharmacological models, GLP toxicology, electrophysiology, and surgical services to support partners in developing drugs, gene/cell therapies, and medical devices for hearing disorders; (2) Therapeutics – advancing proprietary drug candidates including CIL001 (lead compound for cochlear synaptopathy/tinnitus in Phase 2a) and CIL003, leveraging AI and real-world data; and (3) Auditory Analytics – an AI-driven platform developing digital auditory signatures from auditory measurements and biomarkers for early detection of hearing impairment and associated diseases. The company conducts observational clinical studies (DIAMANT, SAPHIR) to characterize auditory profiles in specific patient populations and refine clinical trial protocols.

Differentiator

Problem solved

Functional benefit

Brands

  • CILcare Auditory Analytics: AI-driven hearing analysis platform positioning hearing as a key asset of preventive medicine and global healthcare monitoring, utilizing auditory measurements to define digital auditory signatures.
  • CILcare Therapeutics
  • External Innovation

Products and services

  • CILcare External Innovation (R&D Platform) Comprehensive contract research (CRO) R&D platform offering pharmacological models, GLP toxicology, electrophysiology (ABR, DPOAE, Wave I-V), behavioral assessments (GPIAS, PPI, tinnitus detection), histopathology, inner ear surgery, drug delivery (transtympanic, intracochlear, systemic), and biomarker studies. Used by pharmaceutical, biotech, medtech, and academic clients to evaluate drug candidates, gene therapies, cell therapies, and medical devices for hearing disorders.
  • CIL001 Proprietary lead drug candidate targeting cochlear synaptopathy, the mechanism underlying difficulty understanding speech in noisy environments, tinnitus, and hyperacusis. Advancing through Phase 2a clinical evaluation for tinnitus and other indications, with clinical trials at Massachusetts General Hospital (US) and other sites.
  • CILcare Auditory Analytics AI-driven analytics platform utilizing patient auditory measurements (ABR, DPOAE, speech-in-noise testing) combined with biomarkers and proprietary algorithms/deep learning to define digital auditory signatures for characterizing hearing impairments and supporting early detection of neurocognitive and inflammatory diseases. Used to inform clinical trial patient stratification and preventive medicine positioning.

Quantifiable outcome

  • 26% of cognitively preserved diabetic patients presented clinical signs of hidden hearing loss in DIAMANT study
  • +2 more outcomes

Companies that use CILcare

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

CILcare technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

CILcare partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered flagship and core.

  • SanofiflagshipOEM/ Whitelabel/ Licensing Partner · 23 June 2026Updated license deal with Sanofi who becomes an equity holder, demonstrating deepened commitment to hearing loss therapies. Sanofi has been a long-term licensing partner for hearing-related programs.
  • CBSETcoreStrategic or Co-development Partner · 5 May 2026Nine-year collaboration since 2017 with CBSET, a leading preclinical biomedical research organization in Massachusetts. CBSET is tripling its laboratory capacity, enabling Cilcare to significantly scale up hearing research operations in the US. Together they offer a turnkey model for international companies seeking US market entry.
  • Massachusetts General HospitalcoreStrategic or Co-development Partner · 5 May 2026Clinical trial of CIL001 in tinnitus being conducted at MGH in Boston in partnership with Professor Stéphane Maison, an internationally recognized leader in auditory neuroscience. This marks the first evaluation of CIL001 in patients with chronic tinnitus on US soil.
  • CTIBIOTECHcoreStrategic or Co-development Partner · 10 October 2025Strategic agreement with CTIBIOTECH and SATT AxLR to develop 3D bioprinted inner ear organoids from human induced pluripotent stem cells for pharmacological screening in hearing disorders. The OrgaEar project aims to enable mass production and reduce animal testing.
  • SATT AxLRcoreStrategic or Co-development Partner · 10 October 2025Technology transfer office supporting the OrgaEar project for 3D bioprinted inner ear organoid development in collaboration with CTIBIOTECH and Cilcare.
  • University Hospital Gui de Chauliac (Montpellier)coreStrategic or Co-development PartnerPartner in the SAPHIR observational clinical study investigating hearing impairments in patients with mild cognitive impairment and Parkinson's disease.
  • University Hospital Carémeau (Nîmes)coreStrategic or Co-development PartnerPartner in the SAPHIR study alongside Gui de Chauliac for multicenter, prospective clinical research on hearing and neurodegenerative diseases.
  • Hospices Civils de LyoncoreStrategic or Co-development PartnerPartner in the SAPHIR study for investigating hearing profiles in early-stage neurodegenerative diseases across three patient groups.
  • IDNC (Institute of Diabetology and Nutrition of Centre)coreStrategic or Co-development PartnerPrimary site for the DIAMANT observational clinical study, conducted in association with LNA Health research center, investigating hearing profiles in type 2 diabetes patients.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

CILcare competitors and assessment

Company assessment

Broad incumbents

  • Inotiv: Preclinical CRO with research models and toxicology services including hearing-related endpoints; comparable as a scaled preclinical services competitor to CILcare's CRO division.
  • Charles River Laboratories: Largest preclinical CRO offering broad safety assessment and research models including ototoxicology services; comparable as a potential large-scale competitor in auditory preclinical work.
  • Labcorp Drug Development: Global CRO with extensive central laboratory, bioanalytical, and early development services; comparable end-to-end clinical research services that overlap with CILcare's External Innovation offering.

Direct peers

  • CBSET: Preclinical CRO partner in Massachusetts offering translational research services; directly comparable as a specialty preclinical CRO with cardiovascular/otology capabilities.
  • Akouos: Gene-therapy biotech for inner-ear disorders; comparable specialty therapeutic focus on auditory drug development including modalities CILcare supports as a CRO.
  • Otonomy: Clinical-stage biopharma developing drugs for ear disorders including tinnitus and hearing loss; directly comparable to CILcare's Therapeutics division and lead indication space.
  • Sensorion: French clinical-stage biotech focused on hearing loss therapies including tinnitus and cochlear indications; highly comparable specialty therapeutic-area positioning to CILcare.
  • Frequency Therapeutics: Clinical-stage biotech developing regenerative therapies for hearing loss; comparable therapeutic-area focus and clinical-stage profile to CILcare's CIL001 program.
  • Decibel Therapeutics: Gene-therapy biotech for hearing (acquired by Eli Lilly); directly comparable therapeutic-area focus on cochlear synaptopathy and hearing regeneration pathways.

Emerging players

  • Pipeline Therapeutics: Emerging biotech pursuing regenerative approaches to sensorineural hearing loss; partial overlap in therapeutic area with CILcare's lead indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CILcare social profiles

Digital presence

CILcare financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CILcare leadership team

Management profile

Number of profiles

Profiles8 records

CILcare subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

CILcare funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CILcare M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CILcare

What does CILcare do?

CILcare is a French biotechnology company that provides contract research services (CRO) and develops proprietary drug candidates targeting hearing and ear disorders. Through its External Innovation division, it offers a comprehensive auditory R&D platform spanning in vitro, ex vivo, and in vivo pharmacological models, GLP-compliant ototoxicity studies, electrophysiology, behavioral assessments, histopathology, and surgical capabilities for pharmaceutical, biotech, medtech, and academic clients in Europe, the US, and Asia. Through its Therapeutics division, it advances its own drug pipeline, notably CIL001 for cochlear synaptopathy/tinnitus, and through its Auditory Analytics division, it operates an AI-driven platform that derives digital auditory signatures from patient measurements and biomarkers.

Is CILcare a public or private company?

CILcare is a private company. It is classified as venture growth investor backed and is currently operating.

When was CILcare founded?

CILcare was founded in 2014. It employs 51 to 100 people.

Where is CILcare based?

CILcare is headquartered in Montpellier, France, in the Europe region.

How does CILcare make money?

Two revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are proprietary Drug Development.

Who are CILcare's main competitors?

Broad incumbents on record are Inotiv, Charles River Laboratories and Labcorp Drug Development. Direct peers are CBSET, Akouos, Otonomy, Sensorion, Frequency Therapeutics and Decibel Therapeutics. Pipeline Therapeutics is listed as an emerging player.

Does CILcare have an API?

No public API is recorded for CILcare.

What industry is CILcare in?

CILcare's product category is Hearing Therapeutics R&D Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CilcareCilcare Doubles Down on Hearing Loss: Updates License Deal with Sanofi who becomes equity holderCilcare updated its license agreement for CIL001 and CIL003 with Sanofi, improving royalty terms in exchange for Sanofi becoming a minority shareholder. The deal reflects Cilcare's confidence in its hearing-loss programs, which target over 1.6 billion people with hearing loss.PR NewswireDevelopment of the First Inner Ear Organoids by 3D Bioprinting for Pharmacological Screening in Hearing Disorders: CTIBIOTECH™ Announces Strategic Agreement With SATT AxLR and CILCARECTIBIOTECH was selected by SATT AxLR and CILCARE to develop 3D bioprinted inner ear organoids from human stem cells for hearing disorder research. The project aims to create a non-animal pharmacological screening tool, with a cell-based bioassay market estimated at 28 billion euros by 2028.ShionogiTaking on the Challenge of Untreatable Conditions: Toward a “Future of Hearing” Through Drug DiscoveryShionogi has launched a joint research program with French biotechnology firm Cilcare to develop drug treatments for hearing loss, specifically targeting the protection of auditory nerves. The collaboration focuses on the drug candidate CIL001, which aims to address the significant unmet medical need for effective therapies beyond symptomatic aids like hearing devices.CilcareCilcare completes a €40M series ACilcare closed a €40 million Series A funding round, including €21 million, to support two Phase 2a clinical trials for its drug candidate CIL001 targeting cochlear synaptopathy. The trials, scheduled for 2025, will enroll patients with type 2 diabetes and neurodegenerative disorders. The company will also advance preclinical development for CIL003 and leverage AI for auditory biomarkers.